| Target Molecule | Alarelin Acetate |
| Synonyms | Alarelin, LHRH-A, [D-Ala6, des-Gly10]-LHRH ethylamide, Surfagon |
| CAS Number | 79561-22-1 (acetate / diacetate salt); free base 36622-74-3 |
| Sequence (3-Letter) | pGlu-His-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-NHEt |
| Sequence (1-Letter) | pGlu-HWSYaLR-Pro-NHEt (a = D-Ala; des-Gly10; Pro9 ethylamide) |
| Molecular Formula | C₅₆H₇₈N₁₆O₁₂ (free base) |
| Molecular Weight | 1167.31 (free base) |
| Service Category | Custom Peptide Synthesis / CDMO Manufacturing |
| Synthesis Purity | Customizable (e.g., ≥95%, ≥98% via HPLC) |
| Appearance | White to off-white lyophilized powder |
| Counter Ion | Acetate (standard pharmaceutical salt), TFA, or custom options |
| Synthesis Technology | Solid-Phase Peptide Synthesis (SPPS) and C-Terminal Aminolysis |
| Modification Options | C-terminal ethylamide capping, D-alanine substitution at position 6, stable isotope labeling (13C, 15N), free-acid impurity standards |
| Available Scale | Milligram (R&D) to Kilogram (Commercial CDMO) |
| Analytical Data | Comprehensive COA, HPLC, MS, and C-terminal modification verification provided per batch |
| Usage | Raw material synthesized strictly for laboratory research, analytical development, and industrial formulation. Not a finished medicine. |
Alarelin Acetate (CAS 79561-22-1) is a synthetic nonapeptide GnRH agonist featuring a D-Alanine substitution at position 6 and a non-standard C-terminal proline ethylamide cap (pGlu-His-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-NHEt). We target this sequence to supply high-purity reference materials and raw materials for reproductive endocrinology and veterinary research.
Achieving the C-terminal Pro-ethylamide requires specialized resin cleavage via targeted aminolysis with ethylamine rather than standard acidolytic release. Our peptide synthesis platform combines optimized Solid-Phase Peptide Synthesis (SPPS) with controlled ethylamine aminolysis kinetics to ensure high-yield conversion without chain degradation.
Yes. We provide specialized peptide modification services for GnRH analogues. Options include the synthesis of un-capped free-acid variants as critical impurity reference standards, site-specific stable isotope labeling (13C, 15N) for quantitative mass spectrometry (LC-MS/MS), and fluorescent or biotin tagging.
Our manufacturing infrastructure scales production from milligram-level analytical batches to multigram and kilogram commercial quantities. We optimize preparative HPLC purification and controlled counter-ion exchange (ensuring acetate salt conversion) to guarantee strict batch-to-batch consistency.
We operate as an integrated technical partner providing complete peptide CDMO solutions. Our team manages sequence optimization, aminolysis verification, impurity profiling, analytical method validation, and regulatory documentation to support complex preclinical and commercial pipelines.
Alarelin Acetate (CAS 79561-22-1), widely referenced as LHRH-A or Surfagon, is a synthetic nonapeptide functioning as a potent gonadotropin-releasing hormone (GnRH) receptor agonist. Defined by the sequence pGlu-HWSYaLR-Pro-NHEt (incorporating D-Ala6 and Pro9-ethylamide), it exhibits enhanced metabolic stability and receptor binding affinity compared to native GnRH. Synpeptide provides comprehensive custom synthesis solutions for this target molecule, showcasing our technical expertise in C-terminal aminolysis, non-standard residue assembly, and CDMO manufacturing.
Constructing Alarelin requires precise execution of both internal amino acid substitution and specialized C-terminal functionalization. Standard SPPS yields a free acid or simple amide rather than the requisite ethylamide. Our custom peptide synthesis platform resolves these hurdles using optimized Solid-Phase Peptide Synthesis (SPPS) protocols followed by controlled ethylamine aminolysis during cleavage. By regulating reaction kinetics and temperature parameters, we prevent epimerization and deliver raw materials with rigorous purity specifications (typically ≥95% or ≥98% via HPLC).
Because C-terminal modification efficiency directly dictates product purity, robust analytical validation is essential. Incomplete aminolysis leaves free-acid impurities that closely co-elute with the target peptide. Through our peptide modification services, we synthesize deliberate free-acid variants and deletion analogues to serve as vital reference standards for stability-indicating assays. We also offer site-specific stable isotope labeling (13C, 15N) for pharmacokinetic bioanalysis and fluorescent tags for receptor interaction studies.
Transitioning a C-terminally modified nonapeptide from analytical scale to commercial volume demands robust downstream process engineering, particularly during the aminolysis and purification phases. We execute large-scale peptide synthesis for Alarelin Acetate by optimizing reactor-scale aminolysis parameters and high-capacity preparative HPLC purification. Our facilities accommodate requirements from milligram research batches to kilogram commercial lots, ensuring uniform counter-ion exchange (consistently achieving the pharmaceutical acetate salt form) across all production volumes.
We deliver comprehensive technical support as a fully integrated peptide CDMO. Our development specialists assist pharmaceutical partners with process optimization, stability testing, impurity identification, and analytical method validation. Every batch is released with complete analytical documentation—including COA, HPLC purity traces, and exact mass confirmation—ensuring regulatory alignment for downstream therapeutic programs.
